1. Bayer's stock surged 24.5% since December 2024, yet remains speculative due to significant risks like high debt and ongoing litigation. 2. 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly; Pharmaceuticals saw slight growth, while Crop Science and Consumer Health declined. 3. Bayer's 2025 outlook is uncertain, with potential sales growth of 1% at best; management remains optimistic about a turnaround by 2027. Despite risks, Bayer's extremely low P/E and P/FCF ratios suggest a high upside potential, making it a cautiously optimistic 'Buy' for long-term investors.